Algert Global LLC grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 58.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 419,773 shares of the biopharmaceutical company's stock after purchasing an additional 155,573 shares during the period. Algert Global LLC owned approximately 0.43% of Xenon Pharmaceuticals worth $25,337,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Cinctive Capital Management LP lifted its holdings in Xenon Pharmaceuticals by 1.1% in the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company's stock worth $1,045,000 after buying an additional 263 shares in the last quarter. State of Wyoming increased its position in shares of Xenon Pharmaceuticals by 30.4% during the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company's stock worth $67,000 after acquiring an additional 350 shares during the last quarter. Quarry LP increased its position in shares of Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company's stock worth $100,000 after acquiring an additional 500 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Xenon Pharmaceuticals by 0.7% in the first quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company's stock worth $5,255,000 after acquiring an additional 630 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Xenon Pharmaceuticals by 11.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company's stock worth $295,000 after acquiring an additional 675 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director directly owned 1,455 shares of the company's stock, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gary Patou sold 1,322 shares of the firm's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 12,512 shares of company stock worth $774,088 in the last three months. 2.91% of the stock is owned by insiders.
Xenon Pharmaceuticals Stock Performance
NASDAQ XENE opened at $60.56 on Tuesday. Xenon Pharmaceuticals Inc. has a one year low of $35.60 and a one year high of $72.66. The company has a 50-day simple moving average of $62.48 and a 200-day simple moving average of $55.92. The firm has a market capitalization of $5.85 billion, a PE ratio of -12.78 and a beta of 0.62.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter last year, the business posted ($1.07) EPS. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts recently issued reports on XENE shares. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Royal Bank Of Canada decreased their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating for the company in a report on Friday, August 7th. Needham & Company LLC dropped their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an "overweight" rating in a research note on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $77.13.
Get Our Latest Research Report on XENE
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
